DB
INDV icon

Dmitry Balyasny’s Indivior Pharmaceuticals INDV Stock Holding History

Dmitry Balyasny’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
28,545
+19,424
+213% +$705K ﹤0.01% 2121
2026
Q1 		$278K Buy
+9,121
New +$301K ﹤0.01% 2589
2025
Q2 		– Sell
-54,321
Closed -$518K – 3070
2025
Q1 		$518K Buy
54,321
+17,940
+49% +$189K ﹤0.01% 2258
2024
Q4 		$452K Buy
36,381
+21,379
+143% +$220K ﹤0.01% 2232
2024
Q3 		$146K Sell
15,002
-42,321
-74% -$496K ﹤0.01% 2609
2024
Q2 		$924K Sell
57,323
-120,179
-68% -$2.17M ﹤0.01% 1825
2024
Q1 		$3.8M Buy
+177,502
New +$3.33M 0.01% 1327

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's INDV Position: Q2 2026 in Review

Dmitry Balyasny increased its Indivior Pharmaceuticals (INDV) stake by 213% in Q2 2026, buying an estimated $705K and bringing the position to 28,545 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

Dmitry Balyasny first reported a position in INDV in Q1 2024 and has held it in 7 quarters since. The position peaked at $3.8M in Q1 2024. 335 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Dmitry Balyasny held 28,545 shares of Indivior Pharmaceuticals worth $1.17M as of Q2 2026.
  • Dmitry Balyasny bought 19,424 Indivior Pharmaceuticals shares in Q2 2026, an estimated $705K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2121 holding.
  • Dmitry Balyasny first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Dmitry Balyasny's Indivior Pharmaceuticals position peaked at $3.8M in Q1 2024.
  • 335 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.